Main Products/ Services/ Pipelines & Platforms
TLC BioSciences is a clinical-stage specialty pharmaceutical company developing novel nanomedicines that maximize the potential of its proprietary LipAD® lipid-assembled drug delivery platforms.
LipAD® Platforms: ▪ BioSeizer® - sustained release technology for biologics and/or small molecules ▪ NanoX® - tissue-targeted liposomal delivery with an ionic gradient for active drug loading, proven in 2 approved drugs
Pipeline: ▪ TLC599 (osteoarthritis pain) ▪ TLC590 (postsurgical pain) ▪ TLC399 (macular edema) ▪ TLC178 (advanced malignancies / soft tissue sarcoma) ▪ Ampholipad™ (systemic fungal infections) ▪ ISPM19 (COVID 19 / respiratory diseases)
▪ Out-Licensing ▪ Collaborative R&D ▪ CMO
Ms. Lindsey Yang
Specialist, President’s office